Juniper Pharma Services, a subsidiary of Juniper Pharmaceuticals, has reached a key milestone in its work with CrystecPharma and the Advanced Manufacturing Supply Chain Initiative (AMSCI) to create a new platform to accelerate drug development.
The contract development and manufacturing organisation now has CrystecPharma’s supercritical fluid technology platform on-site. Validation is underway to enable its use in the production of clinical trial materials.
The multi-partner program was initiated to move medicines from research to the market with increased speed and quality. The UK-based consortium expects to be manufacturing drug substance to GMP standard at Juniper’s facility in Nottingham by the end of the summer.
Aimed at drug developers with combination products and compounds that are difficult to crystallise, supercritical fluid technology has been developed to produce better quality drug substances. Less optimisation is required versus traditional development platforms, allowing for quicker scale-up from animal studies to human-ready batches.
Dr. Claire Madden-Smith, senior vice-president at Juniper Pharma Services, said: “Innovation and flexibility is at the heart of the AMSCI project. The work we have carried out with CrystecPharma illustrates the value of supply chain collaboration in enhancing medicine manufacturing and ultimately benefiting patients around the world.”
Paul Thorning, CEO, CrystecPharma, said: “This has never been done before. Our equipment combined with Juniper’s expertise is the only project of its type in the world and is truly innovative in terms of using modified supercritical fluid technology for the manufacture of smarter, higher quality pharmaceutical products.”